Recent Finacing
Recent Raise
Neurogastrx is a Boston-based biopharma developing investigational GI therapies, including fexuprazan (P-CAB) for erosive esophagitis—partnered with Daewoong—and NG101 (D2 antagonist) in Phase 2 for gastroparesis.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Neurogastrx.
